Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
ClC-Kb pore mutation disrupts glycosylation and triggers distal tubular remodeling
Yogita Sharma, Robin Lo, Viktor N. Tomilin, Kotdaji Ha, Holly Deremo, Aishwarya V. Pareek, Wuxing Dong, Xiaohui Liao, Svetlana Lebedeva, Vivek Charu, Neeraja Kambham, Kerim Mutig, Oleh Pochynyuk, Vivek Bhalla
Yogita Sharma, Robin Lo, Viktor N. Tomilin, Kotdaji Ha, Holly Deremo, Aishwarya V. Pareek, Wuxing Dong, Xiaohui Liao, Svetlana Lebedeva, Vivek Charu, Neeraja Kambham, Kerim Mutig, Oleh Pochynyuk, Vivek Bhalla
View: Text | PDF
Research Article Nephrology

ClC-Kb pore mutation disrupts glycosylation and triggers distal tubular remodeling

  • Text
  • PDF
Abstract

Mutations in the CLCNKB gene (1p36), encoding the basolateral chloride channel ClC-Kb, cause type 3 Bartter syndrome. We identified a family with a mixed Bartter/Gitelman phenotype and early-onset kidney failure and by employing a candidate gene approach, identified what we believe is a novel homozygous mutation (CLCNKB c.499G>T [p.Gly167Cys]) in exon 6 of CLCNKB in the index patient. We then validated these results with Sanger and whole-exome sequencing. Compared with wild-type ClC-Kb, the Gly167Cys mutant conducted less current and exhibited impaired complex N-linked glycosylation in vitro. We demonstrated that loss of Gly-167, rather than gain of a mutant Cys, impairs complex glycosylation, but that surface expression remains intact. Moreover, Asn-364 was necessary for channel function and complex glycosylation. Morphologic evaluation of human kidney biopsies revealed typical basolateral localization of mutant Gly167Cys ClC-Kb in cortical distal tubular epithelia. However, we detected attenuated expression of distal sodium transport proteins, changes in abundance of distal tubule segments, and hypokalemia-associated intracellular condensates from the index patient compared with control nephrectomy specimens. The present data establish what we believe are novel regulatory mechanisms of ClC-Kb activity and demonstrate nephron remodeling in humans, caused by mutant ClC-Kb, with implications for renal electrolyte handling, blood pressure control, and kidney disease.

Authors

Yogita Sharma, Robin Lo, Viktor N. Tomilin, Kotdaji Ha, Holly Deremo, Aishwarya V. Pareek, Wuxing Dong, Xiaohui Liao, Svetlana Lebedeva, Vivek Charu, Neeraja Kambham, Kerim Mutig, Oleh Pochynyuk, Vivek Bhalla

×

Figure 4

Asn-364 glycosylation is critical for ClC-Kb function.

Options: View larger image (or click on image) Download as PowerPoint
Asn-364 glycosylation is critical for ClC-Kb function.
(A–C) Voltage-cla...
(A–C) Voltage-clamp experiment shows a reduced conductance in the presence of N-linked glycosylation inhibitor, tunicamycin, compared with vehicle-treated CHO cells (control). Data are mean ± SEM of n = 7–26 samples per condition. *P < 0.05 vs. control by unpaired Student’s t test. (D) Quantification of electrophysiological recordings from CHO cells expressing wild-type (WT) or potential glycosylation-site mutants of ClC-Kb (N364L, N373L, N364L/N373L). Data are mean ± SEM of n = 6–14 samples per condition. *P < 0.05 vs. WT by 1-way ANOVA. (E) Western blot of transfected WT and glycosylation mutants of ClC-Kb in HEK293T cells (probed with anti-HA and anti-cadherin antibodies). (F) Quantitative analysis of protein expression (glycosylated and nonglycosylated) of WT vs. potential glycosylation-site mutants (blue, glycosylated; black, nonglycosylated). Data are mean ± SEM of n = 3 independent experiments. *P < 0.05 vs. glycosylated band for WT; #P < 0.05 for nonglycosylated band vs. WT by 1-way ANOVA. M, marker.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts